A Phase 3 Evaluation of Daclatasvir and Sofosbuvir with Ribavirin in Cirrhotic Subjects with Genotype 3 Chronic Hepatitis C Infection

-
Investigator: Norah A. Terrault, MD
Sponsor: Bristol-Myers Squibb Company

Location(s): United States

Description

The purpose of this study is to determine whether 24 weeks of Daclatasvir and Sofosbuvir with Ribavirin is safe and effective in the treatment of genotype 3 hepatitis C infected patients with liver cirrhosis.